Insulin Lispro
💊 Brand Formulations & Prices
2 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesHumalog 100 is an insulin analogue that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Humalog 100 has a more rapid onset and a shorter duration of action than human regular insulin. Therefore, in patients with type 1 diabetes, Humalog 100
... Read more
Humalog 100 is an insulin analogue that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Humalog 100 has a more rapid onset and a shorter duration of action than human regular insulin. Therefore, in patients with type 1 diabetes, Humalog 100 should be used in regimens that include a longer-acting insulin. However, in patients with type 2 diabetes, Humalog 100 may be used without a longer-acting insulin when used in combination therapy with sulfonylurea agents.
Adult
: SC Dosing regimen should be individualised and adjusted based on patient's glycaemic response. Usual range is 0.5-1 unit/kg/day.
Type 1 diabetes mellitus:
Approximately one third of the total daily insulin requirements SC; rapid-acting or short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements
Usual daily maintenance range
: 0.5-1 unit/kg/day in divided doses; nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.8-1.2 units/kg/day
Type 2 diabetes mellitus:
If inadequately controlled with oral medication: 10 units/day SC (or 0.1 -0.2 unit/kg/day) of intermediate- or long-acting insulin given at bedtime generally recommended; as an alternative, rapid-acting formulations, such as insulin lispro, given before meals have also been used; dose must be adjusted carefully.
Insulin Lispro is contraindicated by patients hypersensitivity to insulin lispro or the other excipients.
Clinical studies comparing Humalog 100 with Regular human insulin did not demonstrate a difference in frequency of adverse events between the two treatments. Adverse events commonly associated with human insulin therapy include the following: Body as a Whole: allergic reactions. Skin and Appendages: injection site reaction, lipodystrophy, pruritus, rash. Other: hypoglycemia.
Renal or hepatic impairment; pregnancy, lactation; transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections.
Insulin Lispro (insulin lispro, rDNA origin) is a human insulin analogue that is a rapid-acting, parenteral blood glucose-lowering agent. Chemically, it is Lys(B28), Pro(B29) human insulin analogue, created when the amino acids at positions 28 and 29 on the insulin B -chain are reversed. Insulin Lispro is synthesized in a special non-pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for insulin lispro. The blood glucose lowering effect of insulin lispro is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.